Recent Posts
- MicroRNA-Mediated Metastasis Suppression
- A New Explanation Of ‘Asian Paradox’
- Toward Bold New Anti-cancer Medicines
- Celsion And Yakult Honsha Announce Treatment Of First Patient In Japan In Celsion’s Global Phase III ThermoDox(R) Trial For Primary Liver Cancer
- $6.5 Million Gift To UCSF From Irwin And Joan Jacobs For Head And Neck Cancer Research
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| « Nov | ||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 | 31 | ||||
Random Posts
- Celleron Therapeutics And Astrazeneca Announce Personalised Medicine Collaboration In Cancer For The Development Of AZ's Leading HDAC Inhibitor
- New e-Science Service Could Accelerate Cancer Research
- Can Kidney Disease Cause Cancer?
- FDA Panel Backs Denosumab for Osteoporosis, But Not Osteopenia
- Vanderbilt Cancer Researcher Wei Zheng Lands MERIT Award
- ECCO-ESMO: No Melanoma Survival Benefit with Targeted Agent (CME/CE)
- Cancer: A Silver Lining?
- DMAA Supports 2009 Almanac Of Chronic Disease, Participates In Document's Release With Partnership To Fight Chronic Disease
- Childhood Cancer Increases Risk of Later Malignancies (CME/CE)
- Cervical Cancer Risk For Women Over 50
Prescription Cancer Drugs
Toward Bold New Anti-cancer Medicines
Posted by: admin in Prescription Cancer Drugs on November 07th, 2009
Bold new strategies in the battle against cancer may turn forms of the disease that presently are incurable into manageable conditions that can be controlled for long periods of time, according to an article in the current issue of Chemical & Engineering News, ACS’ weekly newsmagazine.
C&EN Senior Editor Lisa Jarvis notes that “molecularly targeted” drugs are having a major impact in treating cancer of the breast, colon, and other body parts. Those medications interfere with specific molecules involved in cancer’s growth and spread. However, further advances are critical.
One new strategy involves cutting off cancer cells’ supply of blood sugar, or glucose, and thus starving them to death. Another uses RNA interference, a form of gene therapy in which short RNA segments serve as medication to block the genes involved in cancer. Although scientists face major hurdles in developing effective methods for administering RNA-based medicines, they are making rapid progress in doing so.
Source
Chemical & Engineering News